Mineralys Therapeutics (MLYS)CEO sold ~$230K
Jon Congleton, CEO at Mineralys Therapeutics, sold ~$230K of Mineralys Therapeutics shares.
- ~$230K
- Approx. value · 16K sh @ $14.51
- 846K
- Holds after · shares reported
- Traded
- Jul 11, 2025
- Filed
- Jul 15, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- May 14, 2025InsiderOfficer sold ~$174K of MLYS shares in the open market
- Jun 13, 2025InsiderOfficer sold ~$166K of MLYS shares in the open market
- Jul 11, 2025 · this disclosureInsiderCEO sold ~$230K of MLYS shares in the open market
What came next
- Jul 11, 2025InsiderCFO sold ~$155K of MLYS shares in the open market
- Jul 14, 2025InsiderOfficer sold ~$166K of MLYS shares in the open market
- Jul 28, 2025InsiderCFO sold ~$182K of MLYS shares in the open market
- Jul 29, 2025InsiderCFO sold ~$11K of MLYS shares in the open market
- Jul 30, 2025Insider · 1 personInsiders: 2 sales (~$884K)
- Aug 13, 2025InsiderOfficer sold ~$147K of MLYS shares in the open market
- Sep 4, 2025Insider · 2 peopleInsiders: 2 purchases (~$45.0M)
- Sep 15, 2025Insider · 1 personInsiders: 2 sales (~$409K)
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Mineralys Therapeutics
For Mineralys Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MLYS page.
Other recent filings by Jon Congleton, Chief Executive Officer
- SEC Form 4 at Mineralys Therapeutics (MLYS)Oct 2, 2026
- SEC Form 4 at Mineralys Therapeutics (MLYS)Apr 16, 2025
- SEC Form 4 at Mineralys Therapeutics (MLYS)Jan 16, 2025
- SEC Form 4 at Mineralys Therapeutics (MLYS)Oct 15, 2024
The full history of Jon Congleton, Chief Executive Officer is on the profile page.
How this filing works
Other disclosures at Mineralys Therapeutics
- SEC Form 4Oct 2, 2026
- SEC Form 4Sep 25, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRMay 15, 2026
Everything OQRO holds on this company is on its MLYS page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
